drugset / Trial / NCT06411665

Effect of Oliceridine Analgesia on Postoperative Nause and Vomiting

NCT06411665

Phase 4 Completed 252 enrolled Peking University First Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Postoperative nausea and vomiting (PONV) is common after surgery and impede rapid recovery after surgery. Patients who undergo laparoscopic colorectal surgery are more likely to develop PONV due to the pneumoperitoneum, interruption of gastrointestinal system, delay of oral feeding, and nasogastric catheterization, as well as postoperative opioid analgesic requirement to control acute pain. Oliceridine is a novel selective μ-opioid agonist. It stimulates G protein signalling but is markedly less potent than morphine for β-arrestin recruitment; the latter contributes to opioid-related adverse events including PONV. It is postulated that G protein-biased agonists may deliver effective analgesia with fewer opioid-related adverse events. This randomized trial aimed to investigate whether oliceridine for patient-controlled analgesia can decrease the incidence of PONV in patients recovering from laparoscopic colorectal surgery.

Timeline

Start
2024-07-02
Primary completion
2025-03-14
Completion
2025-04-14

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Morphine Other / unclassified 50 mg Intravenous
Subject Oliceridine Other / unclassified 15 mg Intravenous

Indications

No indication recorded.